ReviewFrontiers in oncology2026
Shaping next decade of systemic therapy for head and neck squamous cell carcinoma: where do we go next?
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Irofulven and RSL3 synergistically target ferroptosis-related gene PTGR1 to treat head and neck squamous cell carcinoma.Open life sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Outcomes of patients with relapsed or metastatic head and neck squamous cell carcinoma (R/M HNSCC) remain poor, despite the widespread incorporation of immune checkpoint inhibitors into contemporary treatment algorithms. Although programmed death-1 (PD-1) blockade with pembrolizumab, administered either alone or in combination with chemotherapy, has become the cornerstone of first line therapy for patients with PD-L1 positive disease, durable clinical benefit is achieved in only a minority of cases. This narrative review explores the most promising systemic treatment strategies expected to shape the management of R/M HNSCC over the coming decade, including bispecific antibodies, HPV directed therapeutic vaccines, antibody-drug conjugates, and other emerging modalities. We discuss their underlying mechanisms of action, review clinical data from early phase studies, and highlight ongoing phase III trials with the potential to redefine future treatment paradigms in R/M HNSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.